Grant ID RP220639
Awarded On September 14, 2022
Title Targeting NHE6 to improve clinical efficacy of daratumumab in myeloma
Program Academic Research
Award Mechanism High Impact/High Risk
Institution/Organization The Methodist Hospital Research Institute
Principal Investigator/Program Director Jing Yang
Cancer Sites Myeloma
Contracted Amount $250,000*

*Pending contract negotiation

Lay Summary

Multiple myeloma (MM) is the second most common blood cancer. A novel FDA-approved antibody-based drug daratumumab (DARA) has shown to improve therapeutic efficacy when combined with common triplet regimens. DARA targets CD38, a protein that is highly expressed on the surface of MM cells; it kills MM cells by triggering antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). However, high-risk MM patients who too often experience relapsed or refractory disease received little benefit from DARA. As a monotherapy, the response rate to DARA remains low. Thus, understanding how MM cells resist to DARA could help us to improve the therapeutic efficacy and surv...

Read More